Animal models of tauopathies

Neuropathology

Volumn 26, Issue 5, 2006, Pages 491-497

  Higuchi, Makoto ^a,b   Saido, Takaomi C ^b   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Alzheimer's disease; Amyloid imaging; Calpain; Frontotemporal lobar degeneration; Neurofibrillary tangle

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[25-35]; CALCIUM ION; CALPAIN; PROTEINASE; TAU PROTEIN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; GENETIC ENGINEERING; MOUSE; MOUSE STRAIN; NERVE DEGENERATION; NERVOUS SYSTEM INJURY; NEUROPATHOLOGY; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; TAU PROTEINS; TAUOPATHIES;

EID: 33748997937     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2006.00685.x     Document Type: Conference Paper

References (34)

1. Higuchi M, Lee VMY, Trojanowski JQ. Pathobiological features in neurodegenerative diseases: an overview. In: Nomura Y, Takeda T, Okuma Y (eds). International Congress Series 1260: The Senescence-Accelerated Mouse (SAM): An Animal Model of Senescence. Amsterdam: Elsevier, 2004; 69-75.
2. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 2003; 62: 363-367.
3. Giasson BI, Forman MS, Higuchi M et al. Initiation and synergistic fibrillization of tau and α-synuclein. Science 2003; 300: 636-640.
4. Selkoe DJ. The cell biology of b-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998; 8: 447-453.
5. Higuchi M, Lee VMY, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med 2002; 2: 131-150.
6. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-1159.
7. Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med 2004; 10 (Suppl): S58-S62.
8. Ishihara T, Hong M, Zhang B et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999; 24: 751-762.
9. Probst A, Gotz J, Wiederhold KH et al. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (Berl) 2000; 99: 469-481.
10. Ishihara T, Zhang B, Higuchi M, Yoshiyama Y, Trojanowski JQ, Lee VM. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am J Pathol 2001; 158: 555-562.
11. Ishihara T, Higuchi M, Zhang B et al. Attenuated neurodegenerative disease phenotype in tau transgenic mouse lacking neurofilaments. J Neurosci 2001; 21: 6026-6035.
12. Hasegawa M, Smith MJ, Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 1998; 437: 207-210.
13. Hong M, Zhukareva V, Vogelsberg-Ragaglia V et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998; 282: 1914-1917.
14. Goedert M, Jakes R, Crowther RA. Effects of frontotemporal dementia FTDP-17 mutations on heparin induced assembly of tau filaments. FEBS Lett 1999; 450: 306-311.
15. Lewis J, McGowan E, Rockwood J et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000; 25: 402-405.
16. Allen B, Ingram E, Takao M et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002; 22: 9340-9351.
17. Tanemura K, Murayama M, Akagi T et al. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J Neurosci 2002; 22: 133-141.
18. Tatebayashi Y, Miyasaka T, Chui DH et al. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci USA 2002; 99: 13896-13901.
19. Zhang B, Higuchi M, Yoshiyama Y et al. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci 2004; 24: 4657-4667.
20. Higuchi M, Ishihara T, Zhang B et al. Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 2002; 35: 433-446.
21. Lin WL, Lewis J, Yen SH, Hutton M, Dickson DW. Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol 2003; 162: 213-218.
22. Zehr C, Lewis J, McGowan E et al. Apoptosis in oligodendrocytes is associated with axonal degeneration in P301L tau mice. Neurobiol Dis 2004; 15: 553-562.
23. Forman MS, Lal D, Zhang B et al. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J Neurosci 2005; 25: 3539-3550.
24. Higuchi M, Zhang B, Forman MS, Yoshiyama Y, Trojanowski JQ, Lee VMY. Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies. J Neurosci 2005; 24: 4657-4667.
25. Lewis J, Dickson DW, Lin WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-1491.
26. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-332.
27. Xie CW. Calcium-regulated signaling pathways: role in amyloid β-induced synaptic dysfunction. Neuromolecular Med 2004; 6: 53-64.
28. Guttmann RP, Johnson GVW. Calpain-mediated proteolysis of neuronal structural proteins. In: Wang KKW, Yuen P-W (eds). Calpain: Pharmacology and Toxicology of Calcium-Dependent Protease. Philadelphia: Taylor & Francis, 1999; 229-249.
29. Higuchi M, Tomioka M, Takano J et al. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J Biol Chem 2005; 280: 15229-15237.
30. 1H-MRI detection of amyloid β plaques in vivo. Nat Neurosci 2005; 8: 527-533.
31. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 1994; 91: 12243-12247.
32. Ishikawa K, Doh-ura K, Kudo Y et al. Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J Gen Virol 2004; 85: 1785-1790.
33. Zhuang ZP, Kung MP, Hou C et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 2001; 44: 1905-1914.
34. 11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse 2004; 52: 283-291.